State Drug Firms Seek Diversification In India
This article was originally published in PharmAsia News
State-run pharmaceutical companies in India seek to take advantage of their large land holdings to diversify into developing commercial complexes in information-technology parks they also run. Bengal Chemicals and Pharmaceuticals is building a large office complex on two acres it owns in Mumbai and plans to lease space while it pursues its drug-development business. Indian Drugs and Pharmaceuticals plans a similar arrangement at the four locations where it will include biotech parks. The state entities still need clearance from a group of government ministers before they can follow through with their diversification plans. (Click here for more
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.